Diagnosis and treatment of schizotypal personality disorder: evidence from a systematic review

ABSTRACT The main objective of this review was to evaluate studies on the diagnosis, treatment, and course of schizotypal personality disorder and to provide a clinical guidance on the basis

of that evaluation. A systematic search in the PubMed/MEDLINE databases was conducted. Two independent reviewers extracted and assessed the quality of the data. A total of 54 studies were

eligible for inclusion: 18 were on diagnostic instruments; 22, on pharmacological treatment; 3, on psychotherapy; and 13, on the longitudinal course of the disease. We identified several

suitable and reliable questionnaires for screening (PDQ-4+ and SPQ) and diagnosing (SIDP, SIDP-R, and SCID-II) schizotypal personality disorder. Second-generation antipsychotics (mainly

risperidone) were the most often studied drug class and were described as beneficial. Studies on the longitudinal course described a moderate remission rate and possible conversion rates to

other schizophrenia spectrum disorders. Because of the heterogeneity of the studies and the small sample sizes, it is not yet possible to make evidence-based recommendations for treatment.

This is a systematic evaluation of diagnostic instruments and treatment studies in schizotypal personality disorder. We conclude that there is currently only limited evidence on which to

base treatment decisions in this disorder. Larger interventional trials are needed to provide the data for evidence-based recommendations. SIMILAR CONTENT BEING VIEWED BY OTHERS ADAPTIVE AND

MALADAPTIVE FEATURES OF SCHIZOTYPY CLUSTERS IN A COMMUNITY SAMPLE Article Open access 17 August 2021 PSYCHOSIS SUPERSPECTRUM II: NEUROBIOLOGY, TREATMENT, AND IMPLICATIONS Article 14

February 2024 AN EXPLORATORY NETWORK ANALYSIS TO INVESTIGATE SCHIZOTYPY’S STRUCTURE USING THE ‘MULTIDIMENSIONAL SCHIZOTYPY SCALE’ AND ‘OXFORD-LIVERPOOL INVENTORY’ IN A HEALTHY COHORT Article

Open access 28 February 2025 INTRODUCTION Schizotypy is a heterogenous syndrome that is expressed across multiple dimensions, including cognitive-perceptual, disorganized, and interpersonal

symptoms1 or according to the symptomology of schizophrenia, positive, negative, and disorganized factors.2,3,4 Raine1 described two types of schizotypy: (1) neurodevelopmental schizotypy

with relatively stable traits and significant brain and neurocognitive impairments that predispose to schizophrenia, and (2) pseudoschizotypy, a pronounced psychosocial entity with more

symptom fluctuation that is unrelated to schizophrenia. Schizotypy, as a broader collection of both clinical and nonclinical traits, is assessed by psychometric inventories such as the

Wisconsin Scales of Schizotypy.3 The assessments for schizotypal traits are mainly used to define a high-risk group and its proneness to psychosis.5 Mason described 16 different schizotypy

scales that were based on clinical concepts or definitions and six scales for psychometric/personality measures of schizotypy.5 According to the theoretical models of Meehl,6,7 Lenzenweger,8

Chapman,9 and Kwapil,10 schizotypy is a premorbid condition. The term schizotypy refers to both people with schizotypal personality disorder (STPD) and healthy individuals in the general

population with certain personality traits and a latent liability for psychosis.1 Consequently, research has been performed in both clinical patients and healthy schizotypal individuals.

Several authors argue for a dimensional approach and a continuum between schizotypal traits and schizophrenia spectrum disorder1,11,12; support for their argument is provided by genetic and

linkage studies showing a considerable overlap between genetic association profiles in schizotypy and schizophrenia.13,14 Since the introduction of the diagnosis of STPD in Diagnostic and

Statistical Manual of Mental Disorders, Third Edition (DSM-III) in 1980, the diagnosis and treatment of STPD have remained difficult because of the lack of evidence-based algorithms. The

original STPD item set was derived from the criteria of borderline schizophrenia seen in the relatives of schizophrenia patients. The differentiation between schizotypal traits and STPD is

clinically important and reflects the degree of impairment in occupational and interpersonal functioning and the severity of symptom presentation.14 This review focuses on the diagnosis of

and therapeutic approaches in patients with a disease severity that fulfills the criteria of STPD not only as a premorbid condition or risk state but also as a separate diagnostic entity.

For years, the International Classification of Diseases (ICD) from the World Health Organization (WHO) and other classification instruments, e.g., the DSM from the American Psychiatric

Association (APA), have differed in their classification of STPD (referred to as _schizotypal disorder_ in the ICD): In ICD-9 and -10, it is listed under schizophrenia spectrum disorders,

whereas in DSM-III to -5 it is classified as a personality disorder. In the forthcoming ICD-11, it will remain in the block of schizophrenia spectrum disorders.15 In DSM-5, a diagnosis of

STPD is defined by the following symptom categories: (1) general impairments in personality and self-functioning (identity and self-direction) and in interpersonal functioning (empathy,

intimacy); (2) STPD-specific pathological personality traits, described as psychoticism, eccentricity, cognitive and perceptual dysregulation, and unusual beliefs and experiences, (3)

detachment characterized by restricted affectivity and withdrawal, and (4) negative affectivity characterized by suspiciousness. In ICD-10,16 and very likely in ICD-11, however, schizotypal

disorder (F21) is characterized by eccentric behavior and changes in thinking and affect similar to those in schizophrenia; the evolution and course of the disease resemble those of a

personality disorder (PD). The prevalence of STPD has been described as ranging from 0.6% in a Norwegian sample to 4.6% in an American sample.17 Men (4.2%) are more often affected than women

(3.7%).17 Common differential diagnoses are other PDs such as the borderline personality disorder (BPD), attention-deficit disorder (inattentive type), social anxiety disorder,

autism-spectrum disorder, and dysthymia.18 Comorbidities can complicate the disease course and treatment responses, and several studies focus on interventions for patients with comorbid

obsessive-compulsive disorder (OCD)19 and BPD. Schizotypy occurs more often in relatives of patients with schizophrenia or a Cluster A PD. Twin studies showed highly stable genetic factors

and rather transient environmental factors for an increased risk for the schizotypal syndrome,20 and genetic risk variants for schizophrenia could also be linked to STPD.21,22,23 The

conversion rates from STPD to schizophrenia spectrum disorders vary between 20 and >40%, depending on the follow-up interval.1,24 Imaging studies detected numerous group-level differences

in the size of specific brain regions in individuals with STPD or schizotypy in comparison with healthy participants, patients with schizophrenia, and patients with other PDs.18 Despite

these research efforts, evidence-based recommendations are still lacking for the diagnosis and treatment of STPD. National and international treatment guidelines for schizophrenia spectrum

disorders (e.g., from the APA, the National Institute for Health and Care Excellence and World Federation of Societies of Biological Psychiatry (WFSBP)) do not discuss this topic, and

specific guidelines for personality disorders pay only little attention to STPD.25 Rosell et al.18 recently published a non-systematic literature review on the epidemiology, functional

impairment, heritability and genetics, cognitive impairments, social-affective disturbances, and neurobiology of STPD. This detailed review provides a deeper insight into the pathophysiology

of and experimental research on STPD and includes information on imaging and genetic and psychological testing.18 Nevertheless, it remains unclear which diagnostic tools, medication, or

psychotherapy are recommended. Therefore, the main objective of this systematic review, which was based in principle on the recommendation of the Preferred Reporting Items for Systematic

Reviews and Meta-Analyses group,26 was to evaluate the literature on the diagnosis and treatment of patients seeking help for STPD. In addition, it offers some information on the

longitudinal course of STPD and conversion rates to other schizophrenia spectrum disorders. RESULTS ARTICLES ON DIAGNOSTIC INSTRUMENTS STUDY CHARACTERISTICS When examining the articles on

diagnostic instruments, we focused on studies that tested disease criteria27,28,29,30,31 and clinical diagnostic questionnaires for STPD.32,33,34,35,36,37,38,39 One study did not

specifically evaluate a diagnostic questionnaire but compared a factor analysis model with established questionnaires.40 INDIVIDUAL OUTCOMES Five studies aimed at evaluating the variables of

the diagnostic criteria, the shifts in diagnosis from DSM-III to -5 or ICD-8 to -10 and their effect on diagnostic sensitivity, specificity, and diagnostic overlap,27,28,30,31,41 as

indicated in Table 1. The reliability of the DSM-III criteria had an adequate mean kappa of 0.71.27 In DSM-III, the diagnoses of BPD and STPD interacted on the symptom level.27 In DSM-III-R,

the threshold for an STPD diagnosis was raised, and the number of STPD diagnoses consequently decreased by 40%. This offered a sharper discrimination between STPD and related PDs, such as

BPD and schizoid PD.30 In the evolution of the ICD system, the threshold for meeting symptom criteria was also crucial for differential diagnosis: Whereas in ICD-8/-9 less patients would

have been diagnosed with STPD, in ICD-10 the threshold was lowered and more patients were diagnosed with STPD. In the ICD system, the severity of the disease may mark the discrimination

between STPD and schizophrenia, which would favor a dimensional diagnosis concept.31 Most of the studies evaluated the inter-rater reliability (which ranged from 0.62 to 0.91) and

test–retest reliabilities (which ranged from 0.64 to 0.84) of the diagnostic instruments; reliabilities were adequate (see Table 1). Among the diagnostic instruments, three were identified

as being suitable for diagnosis because they had adequate reliabilities and validities for the respective diagnostic criteria: the Structured Interview for DSM-III Personality Disorder

(SIDP),33 the Semi-structured Interview for DSM-III-R Personality Disorders (SIDP-R),35 and the Structured Clinical Interview for DSM-IV (SCID-II)37 (see Table 1). The self-report

instruments Schizotypal Personality Questionnaire (SPQ) and Schizotypal Personality Questionnaire—Brief (SPQ-B) were designed as screening instruments for STPD. The SPQ-B shows adequate

internal consistency (coefficient kappa = 0.87),42 and the SPQ shows strong correlations between patients’ responses and SCID-II–rated symptoms.38,43 The Personality Diagnostic

Questionnaire-4+ (PDQ-4+) is also a self-report instrument for diagnosing PD. It has more false-positive results than the SCID-II and is therefore only useful as a screening tool for PDs but

not as a diagnostic tool.44 The Minnesota Multiphasic Personality Inventory (MMPI) could not differentiate between individuals with STPD and schizophrenia.45 However, a distinct profile

(MMPI 2-7-8) showed an enrichment of diagnoses of Cluster A PDs when compared with SIDP-IV interviews. None of the instruments was designed to evaluate disease severity. Three studies

compared diagnostic interviews with factor analysis models.35,40,44 According to Battaglia et al.35, the three factors cognitive-perceptual, interpersonal, and oddness best describe the

diagnosis of STPD; Fossati et al.37 made the same statement, but these two studies had overlapping patient cohorts. Sanislow et al.40 developed a four-factor model and argued that it was

significantly better than the established unitary “generic” model.40 Please see Table 1 for details. ARTICLES ON INTERVENTIONAL DRUG TREATMENT TRIALS STUDY CHARACTERISTICS Most of the

studies were prospective double-blind, placebo-controlled trials,46,47,48,49,50,51,52,53,54,55,56 and all publications reported single-center results. We also identified one double-blind,

treatment-controlled trial;57 one single-blind, placebo-controlled trial;58 four open-label trials;59,60,61,62 one retrospective study;63 and four case reports.64,65,66,67 Please see Table

2A, B and Supplementary Table 3 and 4 for further study details and level of evidence (LoE) grading. In total, 16 individual drug treatments were studied. The most frequently studied drug

was risperidone,50,53,54,62 and the most frequently studied class of drugs were the antipsychotics,47,48,50,53,54,57,58,59,60,62,63,66 followed by the antidepressants.46,61,64,65 Six studies

tested other neuroactive drugs.49,51,52,55,56,67 In most studies, the main outcome measurement was a general psychiatric symptom scale, such as the Brief Psychiatric Rating Scale,60,63,67

the Hopkins Symptom Checklist,48,61 and the Psychiatric Assessment Interview.57 Three trials used interviews for specific psychotic symptoms, such as the Positive and Negative Symptom Scale

(PANSS).50,53,56 Some studies focused on patients with comorbidities of OCD or BPD and consequently measured outcome with the Yale-Brown Obsessive Compulsive Scale (YBOCS)46,48,59,66 or the

Self-Injurious Behavior scale.47 One study used a specific tool, the SPQ, to assess the severity of STPD as an additional outcome measurement tool.50 Common secondary outcome tools were

measurements for global functioning, i.e., the Global Assessment of Symptoms60 and Clinical Global Impression,50 or for depressive symptoms, i.e., the Hamilton Rating Scale for

Depression.46,50,62 Six studies had cognitive measures, i.e., working memory,49,52,55 context processing,51 reaction time,54 response inhibition,54 or a combination of different cognitive

categories,53 as a primary or secondary outcome. INDIVIDUAL OUTCOMES Most of the studies on an antipsychotic drug intervention found a positive effect in STPD (see Table 2A). Thiothixine

reduced general symptoms (especially illusions, ideas of reference, paranoid ideation, cognitive deficits, and anxiety) in cohorts of mixed BPD and STPD patients, but the respective studies

found no significant relationship between diagnosis and outcome of treatment.47,57 Risperidone was the only drug that was evaluated in studies that fulfilled relevant study quality criteria,

such as reporting effect sizes, being randomized, and using quantitative measures and standardized questionnaires. It was evaluated in four independent studies: Koenigsberg et al. showed a

reduction in the PANSS score in STPD but no difference in the STPD-specific SPQ;50 Rabella et al. reported an improvement in reaction time after treatment with risperidone;54 McClure et al.

found no beneficial effect of risperidone in either the PANSS or cognitive measurements;53 and the open-label study by Rybakowski et al. found an increase in social and occupational

functioning and cognitive tests after risperidone treatment.62 In an open-label augmentation trial, a small cohort (_n_ = 11) of patients with STPD had significant improvements in psychosis

and depression ratings when treated with olanzapine.60 In an open-label study in patients with comorbid OCD and STPD, a combination of fluvoxamine and olanzapine showed beneficial effects,

i.e., it reduced the YBOCS score,59 and the concomitant diagnosis of STPD was significantly associated with a positive response. In a retrospective study, Di Lorenzo et al. reported a

decrease of general symptoms when patients with schizophrenia spectrum disorder were treated with aripiprazole; patients with STPD were included, but no specific results were mentioned.63 In

one case report, clozapine treatment reduced symptoms in a patient with comorbid OCD and STPD.66 Three studies investigating the use of antipsychotics analyzed mixed cohorts of STPD and BPD

patients,47,48,57 and one study analyzed patients with schizophrenia spectrum disorder.63 Studies evaluating antidepressant treatment examined only mixed (BPD and STPD) or comorbid (OCD and

STPD) cohorts (see Table 2B). In an open-label trial of fluoxetine, Markovitz et al. measured a reduction of general symptoms in patients with BPD, STPD, or both,61 regardless of the

diagnosis. In another study, clomipramine showed no significant effects on OCD symptoms in a cohort of patients with OCD and STPD, and the authors reported a worse treatment outcome in

patients with comorbid STPD than in those with other PD diagnoses.46 One case report described a patient with STPD who developed psychotic symptoms after treatment with fluoxetine,64 and

other case reports showed positive effects of clomipramine, paroxetine, and buspirone on depressive or OCD symptoms46,65 (see Supplementary Tables 3C and D). Five studies tested other

substances and their effect on cognitive impairments in patients with STPD (see Supplementary Table 3): On the basis of studies showing positive results of catecholamine agonistic treatment

in schizophrenia-related disorders, Siegel et al. tested d-amphetamine in a cohort of patients with STPD and found an improvement in the Wisconsin Card Sorting Test (WCST); however, the

authors found no effect of symptom change on the PANSS score.56 Two studies tested dopamine agonists (pergolide and dihydrexidine) and showed improvements in working and verbal memory,

executive functioning, information processing, and divided attention.52,55 Two studies tested modulators of the autonomous nervous system (intravenous physostigmine, a cholinesterase

inhibitor and enhancer of the parasympathetic nervous system, and guanfacine, an α2A receptor agonist and sympatholytic drug) and their effect on cognition. These studies showed improvements

in verbal memory, visuospatial working memory, and context processing.49,51 The sizes of the studies varied between 1 patient with STPD in a larger mixed cohort63 and up to 31 patients with

STPD53 (see Supplementary Table 2). ARTICLES ON PSYCHOTHERAPY STUDY CHARACTERISTICS We identified one randomized clinical trial that compared integrated therapy with standard treatment,68

one uncontrolled clinical trial,69 and one case report of a patient with OCD and comorbid STPD.70 The sizes of the studies varied from 170 to 7968 patients with a diagnosis of STPD (see

Supplementary Table 2). INDIVIDUAL OUTCOMES An uncontrolled prospective trial of a psychodynamic day-care treatment program found no benefit for STPD patients.69 One case report showed a

reduction of symptoms in a patient with STPD and OCD70 after social skills training. Another trial also reported a positive effect of social skills training, i.e., STPD patients with this

training had a lower transition rate from STPD to a psychotic disorder.68 We found no trial that evaluated cognitive behavioral therapy in STPD (see Table 3). ARTICLES ON LONGITUDINAL COURSE

AND FOLLOW-UP STUDIES STUDY CHARACTERISTICS We included eight studies of clinical cohorts.71,72,73,74,75,76,77,78 Studies with mixed clinical and non-clinical cohorts were included if they

predicted the development of an STPD diagnosis from childhood to adulthood or the conversion rate to psychotic illness.79,80,81 One article focused of the stability of a diagnosis of STPD in

young adult twins.20 The study size depended on the investigated cohort (for details see Supplementary Table 2). INDIVIDUAL OUTCOMES The follow-up periods of the studies ranged from a

minimum of 1 year81 to 27 years.80 In a mixed cohort of healthy and mentally ill children, Bernstein et al. showed that an early STPD diagnosis during adolescence rarely persisted over a

2-year follow-up period.79 Along the same lines, in their study in adults Grilo et al. reported a remission of the STPD diagnosis in 61% of patients and suggested that, although maladaptive

traits may persist, the severity of symptoms can change.76 In contrast, Asarnow et al. showed that children with a diagnosis of STPD mostly kept the diagnosis, but 25% of them developed more

severe schizophrenia spectrum disorders (schizophrenia or schizoaffective disorder).81 Olin et al. evaluated the relationship between personality traits and disorders in a community-based

cohort of healthy and mentally ill children and concluded that early traits can be predictive for the development of an STPD. Four studies evaluated longitudinal global functioning and

impairment:71,72,73,74 Impairments in global functioning and social impairment differed depending on the study sample, but, overall, patients with pure STPD had less impairment than patients

with other comorbid PDs or SZ. In particular, patients with comorbid BPD had poor global functioning. Treatment with antipsychotic medication was common in STPD patients.74,75 They were

also frequently hospitalized and received psychotherapy.75 Two studies evaluated the stability of symptoms over time: McGlashan et al. found paranoid ideation and unusual experiences to be

the most stable, whereas oddness appeared to be the least prevalent and most changeable;78 and Kendler et al. studied the stability of Cluster A PDs in twins and concluded that genetic risk

factors lead to highly stable subtypes of the disorder, whereas shared environmental risk factors lead to rather transient symptoms20 (see Table 4). Two studies focused on the conversion

from STPD to a psychotic illness and found rates of 25–48%.24,82 QUALITY OF THE STUDIES The composition and size of the cohorts varied greatly across the studies, and all treatment studies

were single center. Some studies in mixed samples of patients reported results on very few or only single STPD patients. It remains questionable whether the results of these studies can be

applied to a larger group of patients with STPD. Most of the articles did not mention disease severity because of a lack of a suitable measurement tool. A variety of methods for evaluating

the quality of diagnostic instruments, the outcome of clinical interventional studies (drug treatment or psychotherapy), or longitudinal outcome were applied across the studies, resulting in

a high heterogeneity and hampering comparability. DISCUSSION We present a systematic review of diagnostic instruments and pharmacological and psychosocial treatment strategies for STPD.

After performing a standardized and systematic literature search and analysis, we assessed 94 full-text articles for eligibility and evaluated 54 of them. At this point, it would be

premature to make clear recommendations for the use of specific diagnostic instruments or drug or psychotherapy treatment approaches. Our evaluation of diagnostic instruments made clear that

the diagnosis of STPD has changed over time. In each diagnostic system, the threshold for meeting symptom criteria seems to differentiate between related diseases, such as other PDs or

schizophrenia. Nearly all the diagnostic instruments discussed for STPD have adequate inter-rater and test–retest reliability. Our review confirms that the SIDP for DSM-III, SIDP-R for

DSM-III-R, and SCID-II for DSM-IV are suitable for diagnosing STPD, but we found that the diagnostic tool PDQ-4+ is more suitable for screening. Factor analysis models are frequently

discussed as a diagnostic alternative to catalogs with rather arbitrary diagnostic criteria. A complete review of the scales used to access schizotypy as a broad concept can be found in the

review by Mason, which focuses not only on the clinical diagnosis but also on psychometric measurements that assess schizotypal personality traits and define a high-risk group for

schizophrenia.5 Longitudinal studies examined the stability of the diagnostic entity and observed moderate-to-high remission rates between an early childhood onset and later adulthood.

Patients suffering of comorbid BPD showed poorer social functioning than patients with pure STPD.71,72 Yet, drug treatment responses in patients with comorbid BPD were regardless of the

diagnosis.47,57,61 Patients suffering of a comorbid OCD showed better response rates after treatment with olanzapine59 and poorer responses after clomipramine treatment.46 The articles on

treatment clearly showed that antipsychotics are the most frequently used drugs. When we considered only studies that were of acceptable methodological quality (see LoEs in Tables 2 and 3

and Supplementary Table 3 and 4), risperidone had the best, but still limited, evidence for reducing clinical symptoms in patients with STPD. Antidepressants have only been tested in mixed

cohorts (patients with comorbid OCD or BPD), making it difficult to draw definite conclusions on their effectiveness in STPD. Most of the drug treatment studies were conducted in patients

with STPD and a comorbid disorder, which also limits our ability to draw conclusions. Moreover, some studies included only a few patients, resulting in an LoE of 2− to 3. Remarkably, to the

best of our knowledge no treatment guidelines or Cochrane Collaboration reviews exist that provide a comprehensive discussion of treatment alternatives for STPD. The WFSBP Guidelines for

Biological Treatment of Personality Disorders provide only general recommendations for antipsychotics on the basis of minimal evidence from clinical trials and expert opinion (Herpertz et

al. 2007). In summary, our systematic review shows that the best evidence for efficacy in STPD is available for risperidone and to a limited extent for olanzapine. The literature on

psychotherapy is sparse and does not allow us to make any recommendations, although social skills training seems to be effective and should be offered to patients with STPD. Large-scale

naturalistic and interventional trials with defined diagnostic cohorts and strict study designs are needed to provide the data for more detailed evidence-based recommendations. METHODS STUDY

SELECTION This systematic review was conducted by searching the PubMed/MEDLINE databases for papers published at any time. We conducted the final search on September 14, 2016, at which time

the data source contained studies from April 1, 1947, to August 21, 2016. A total of 145 combinations of search terms were used to search the databases with the ENDNOTE X7 search tools (see

Supplementary Information). Duplicates were removed by using the ENDNOTE X7 duplication detection feature. The publications (titles and abstracts) were then screened for relevance. To be

included, the articles had to report on studies of original data and focus on the diagnosis, treatment, or follow-up of patients with STPD. Because including only studies with a Scottish

Intercollegiate Guidelines Network (SIGN) LoE of 1− to 1++ would have limited the number of studies available for inclusion, we included not only randomized control trials but also cohort

studies, retrospective non-analytical studies, and case studies (LoE 2++ to 3). Expert opinions (LoE 4) were not considered. Study designs and LoE grading are described in the Tables 2A, B,

and 3, and Supplementary Tables 3 and 4. Reviews, meta-analyses, and non-English publications were excluded. Two reviewers independently analyzed the full-text publications and retrieved

data on clinical diagnosis and treatment. We searched also three additional databases (WHO Clinical Trials (http://apps.who.int/trialsearch/), ClinicalTrials (https://clinicaltrials.gov/),

and the Cochrane Library (http://www.cochranelibrary.com/)) for ongoing or planned clinical trials and for systematic reviews or meta-analyses. Using the search term “schizotypal personality

disorder,” we identified 18 clinical trials. Furthermore, we found two additional trials that had been completed; however, upon closer inspection it became clear that they did not meet the

inclusion criteria for this systematic review. We identified one protocol83 in the Cochrane Library, but it was withdrawn with no results in 2014. Our search strategy yielded 3420 unique

studies, 3326 of which were excluded after we had screened the titles, abstracts, and article format reviews, resulting in 94 full-text articles. These 94 articles were scanned for the

inclusion criteria of this systematic review—to be included, studies had to investigate diagnostic instruments for or the treatment or longitudinal course of STPD. After full-text screening,

38 articles had to be excluded because they did not include original data or were not about clinical patients with STPD. The remaining 56 articles were sorted into the following categories:

clinical diagnostic instruments (18 studies), pharmacological treatment (22 studies), psychotherapy (3 studies), and longitudinal course and follow-up (13 studies) (see Supplementary

Information). Publications on diagnostic questionnaires were only included if they evaluated diagnostic criteria or questionnaires as assessment tools. Articles on factor analysis models

alone were excluded, and publications on drug treatment were excluded if there was no report of a clinical outcome. We identified three overlapping patient cohorts: one in the articles on

diagnostic instruments (Battaglia et al.35 and Fossati et al.44); one in the articles on drug treatment (Goldberg et al. 198647 and 198748); and one in the Chestnut Lodge cohort (McGlashan

et al. published an article on testing DSM-III criteria29 and a 2-year follow-up study in a separate article72). GENERAL STUDY CHARACTERISTICS We assumed a large heterogeneity in disease

severity among the included patients who were recruited in outpatient and inpatient settings. Because of the inconsistent outcome measures in the interventional groups, in our view the

available data were not suited to perform quantitative analyses, e.g., with a meta-analytical approach. Some study populations included also healthy and population-based individuals, but

these studies were only taken into consideration when a clinical diagnosis of STPD was mentioned.20,34,36,38,79,80 Most of the studies focused on adults, although three focused on children

and the longitudinal course of their diseases.79,80,81 The study sizes varied greatly, as indicated in Supplementary Table 2. DATA AVAILABILITY This is a systematic review. All data

generated or analyzed during this study is included in this published article (or Supplementary Information). No other data are available. REFERENCES * Raine, A. Schizotypal personality:

neurodevelopmental and psychosocial trajectories. _Annu. Rev. Clin. Psychol._ 2, 291–326 (2006). Article  Google Scholar  * Fonseca-Pedrero, E. et al. The structure of schizotypal

personality traits: a cross-national study. _Psychol. Med._ 48, 451–462 (2018). Article  CAS  Google Scholar  * Kwapil, T. R., Barrantes-Vidal, N. & Silvia, P. J. The dimensional

structure of the Wisconsin Schizotypy Scales: factor identification and construct validity. _Schizophr. Bull._ 34, 444–457 (2008). Article  Google Scholar  * Kwapil, T. R., Gross, G. M.,

Silvia, P. J., Raulin, M. L. & Barrantes-Vidal, N. Development and psychometric properties of the Multidimensional Schizotypy Scale: a new measure for assessing positive, negative, and

disorganized schizotypy. _Schizophr. Res._ 193, 209–217 (2018). Article  Google Scholar  * Mason, O. J. The assessment of schizotypy and its clinical relevance. _Schizophr. Bull._ 41(Suppl

2), S374–S385 (2015). Article  Google Scholar  * Meehl, P. E. Schizotaxia, schizotypy, schizophrenia. _Arch. Gen. Psychiatry_ 46, 935–944 (1962). Article  Google Scholar  * Meehl, P. E.

Toward an integrated theory of schizotaxia. _J. Pers. Disord._ 4, 1–99 (1990). Article  Google Scholar  * Lenzenweger, M. F. Schizotypy, schizotypic psychopathology and schizophrenia. _World

Psychiatry_ 17, 25–26 (2018). Article  Google Scholar  * Chapman, L. J. et al. Impulsive nonconformity as a trait contributing to the prediction of psychotic-like and schizotypal symptoms.

_J. Nerv. Ment. Dis._ 172, 681–691 (1984). Article  CAS  Google Scholar  * Kwapil, T. R. & Barrantes-Vidal, N. Schizotypy: looking back and moving forward. _Schizophr. Bull._ 41(Suppl

2), S366–S373 (2015). Article  Google Scholar  * Ettinger, U., Meyhofer, I., Steffens, M., Wagner, M. & Koutsouleris, N. Genetics, cognition, and neurobiology of schizotypal personality:

a review of the overlap with schizophrenia. _Front. Psychiatry_ 5, 18 (2014). Article  Google Scholar  * Fonseca-Pedero, E. D. M. Schizotypal traits and psychotic-like experiences during

adolescence: an update. _Psicothema_ 29, 5–17 (2017). Google Scholar  * Fanous, A. H. et al. Significant correlation in linkage signals from genome-wide scans of schizophrenia and

schizotypy. _Mol. Psychiatry_ 12, 958–965 (2007). Article  CAS  Google Scholar  * Walter, E. E., Fernandez, F., Snelling, M. & Barkus, E. Genetic consideration of schizotypal traits: a

review. _Front. Psychol._ 7, 1769 (2016). Article  Google Scholar  * Gaebel, W., Zielasek, J. & Cleveland, H. R. Classifying psychosis--challenges and opportunities. _Int. Rev.

Psychiatry_ 24, 538–548 (2012). Article  Google Scholar  * World Health Organization. _The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic

guidelines_ (World Health Organization, 2016) http://www.who.int/classifications/icd/en/bluebook.pdf. * Pulay, A. J. et al. Prevalence, correlates, disability, and comorbidity of DSM-IV

schizotypal personality disorder: results from the wave 2 national epidemiologic survey on alcohol and related conditions. _Prim. Care. Companion J. Clin. Psychiatry_ 11, 53–67 (2009).

Article  Google Scholar  * Rosell, D. R., Futterman, S. E., McMaster, A. & Siever, L. J. Schizotypal personality disorder: a current review. _Curr. Psychiatry Rep._ 16, 452 (2014).

Article  Google Scholar  * Sobin, C. et al. Evidence of a schizotypy subtype in OCD. _J. Psychiatr. Res._ 34, 15–24 (2000). Article  CAS  Google Scholar  * Kendler, K. S. et al. A

longitudinal twin study of cluster A personality disorders. _Psychol. Med._ 45, 1531–1538 (2015). Article  CAS  Google Scholar  * Bilder, R. M. et al. Neurocognitive correlates of the COMT

Val(158)Met polymorphism in chronic schizophrenia. _Biol. Psychiatry_ 52, 701–707 (2002). Article  CAS  Google Scholar  * Nyegaard, M. et al. CACNA1C (rs1006737) is associated with

schizophrenia. _Mol. Psychiatry_ 15, 119–121 (2010). Article  CAS  Google Scholar  * Hodgkinson, C. A. et al. Disrupted in schizophrenia 1 (DISC1): association with schizophrenia,

schizoaffective disorder, and bipolar disorder. _Am. J. Hum. Genet._ 75, 862–872 (2004). Article  CAS  Google Scholar  * Debbane, M. et al. Developing psychosis and its risk states through

the lens of schizotypy. _Schizophr. Bull._ 41(Suppl 2), S396–S407 (2015). Article  Google Scholar  * Herpertz, S. C. et al. World Federation of Societies of Biological Psychiatry (WFSBP)

guidelines for biological treatment of personality disorders. _World J. Biol. Psychiatry_ 8, 212–244 (2007). Article  Google Scholar  * Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G.

& Group, P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. _Ann. Intern. Med._ 151, 264–269 (2009). W264. Article  Google Scholar  *

Jacobsberg, L. B., Hymowitz, P., Barasch, A. & Frances, A. J. Symptoms of schizotypal personality disorder. _Am. J. Psychiatry_ 143, 1222–1227 (1986). Article  CAS  Google Scholar  *

Widiger, T. A., Frances, A., Warner, L. & Bluhm, C. Diagnostic criteria for the borderline and schizotypal personality disorders. _J. Abnorm. Psychol._ 95, 43–51 (1986). Article  CAS 

Google Scholar  * McGlashan, T. H. Testing DSM-III symptom criteria for schizotypal and borderline personality disorders. _Arch. Gen. Psychiatry_ 44, 143–148 (1987). Article  CAS  Google

Scholar  * Vaglum, P., Friis, S., Vaglum, S. & Larsen, F. Comparison between personality disorder diagnoses in DSM-III and DSM-III-R: reliability, diagnostic overlap, predictive

validity. _Psychopathology_ 22, 309–314 (1989). Article  CAS  Google Scholar  * Handest, P. & Parnas, J. Clinical characteristics of first-admitted patients with ICD-10 schizotypal

disorder. _Br. J. Psychiatry Suppl._ 48, s49–s54 (2005). Article  Google Scholar  * Perry, J. C., O’Connell, M. E. & Drake, R. An assessment of the schedule for schizotypal personalities

and the DSM-III criteria for diagnosing schizotypal personality disorder. _J. Nerv. Ment. Dis._ 172, 674–680 (1984). Article  CAS  Google Scholar  * Stangl, D., Pfohl, B., Zimmerman, M.,

Bowers, W. & Corenthal, C. A structured interview for the DSM-III personality disorders. A preliminary report. _Arch. Gen. Psychiatry_ 42, 591–596 (1985). Article  CAS  Google Scholar  *

Raine, A. The SPQ: a scale for the assessment of schizotypal personality based on DSM-III-R criteria. _Schizophr. Bull._ 17, 555–564 (1991). Article  CAS  Google Scholar  * Battaglia, M.,

Cavallini, M. C., Macciardi, F. & Bellodi, L. The structure of DSM-III-R schizotypal personality disorder diagnosed by direct interviews. _Schizophr. Bull._ 23, 83–92 (1997). Article 

CAS  Google Scholar  * Merritt, R. D., Balogh, D. W. & Kok, C. J. DSM-IV Cluster A personality disorder diagnoses among young adults with a 2-7-8 MMPI profile. _Assessment_ 5, 273–285

(1998). Article  CAS  Google Scholar  * Fossati, A. et al. Latent class analysis of DSM-IV schizotypal personality disorder criteria in psychiatric patients. _Schizophr. Bull._ 27, 59–71

(2001). Article  CAS  Google Scholar  * Dickey, C. C. et al. Clinical, cognitive, and social characteristics of a sample of neuroleptic-naive persons with schizotypal personality disorder.

_Schizophr. Res._ 78, 297–308 (2005). Article  Google Scholar  * Morey, L. C., Benson, K. T. & Skodol, A. E. Relating DSM-5 section III personality traits to section II personality

disorder diagnoses. _Psychol. Med._ 46, 647–655 (2016). Article  CAS  Google Scholar  * Sanislow, C. A. et al. Confirmatory factor analysis of DSM-IV borderline, schizotypal, avoidant and

obsessive-compulsive personality disorders: findings from the Collaborative Longitudinal Personality Disorders Study. _Acta Psychiatr. Scand._ 105, 28–36 (2002). Article  Google Scholar  *

McGlashan, T. H. Recovery style from mental illness and long-term outcome. _J. Nerv. Ment. Dis._ 175, 681–685 (1987). Article  CAS  Google Scholar  * Axelrod, S. R., Grilo, C. M., Sanislow,

C. & McGlashan, T. H. Schizotypal Personality Questionnaire-Brief: factor structure and convergent validity in inpatient adolescents. _J. Pers. Disord._ 15, 168–179 (2001). Article  CAS

  Google Scholar  * Ryder, A. G., Costa, P. T. & Bagby, R. M. Evaluation of the SCID-II personality disorder traits for DSM-IV: coherence, discrimination, relations with general

personality traits, and functional impairment. _J. Pers. Disord._ 21, 626–637 (2007). Article  Google Scholar  * Fossati, A. et al. Taxonic structure of schizotypal personality disorder: a

multiple-instrument, multi-sample study based on mixture models. _Psychiatry Res._ 137, 71–85 (2005). Article  Google Scholar  * Matsui, M., Sumiyoshi, T., Niu, L., Kurokawa, K. &

Kurachi, M. Minnesota Multiphasic Personality Inventory profile characteristics of schizotypal personality disorder. _Psychiatry Clin. Neurosci._ 56, 443–452 (2002). Article  Google Scholar

  * Baer, L. et al. Effect of axis II diagnoses on treatment outcome with clomipramine in 55 patients with obsessive-compulsive disorder. _Arch. Gen. Psychiatry_ 49, 862–866 (1992). Article

  CAS  Google Scholar  * Goldberg, S. C. et al. Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. _Arch. Gen. Psychiatry_ 43, 680–686 (1986).

Article  CAS  Google Scholar  * Goldberg, S. C., Schulz, S. C., Resnick, R. J., Hamer, R. M. & Schulz, P. M. Differential prediction of response to thiothixene and placebo in borderline

and schizotypal personality disorders. _Psychopharmacol. Bull._ 23, 342–346 (1987). CAS  PubMed  Google Scholar  * Kirrane, R. M., Mitropoulou, V., Nunn, M., Silverman, J. & Siever, L.

J. Physostigmine and cognition in schizotypal personality disorder. _Schizophr. Res._ 48, 1–5 (2001). Article  CAS  Google Scholar  * Koenigsberg, H. W. et al. Risperidone in the treatment

of schizotypal personality disorder. _J. Clin. Psychiatry_ 64, 628–634 (2003). Article  CAS  Google Scholar  * McClure, M. M. et al. The effects of guanfacine on context processing

abnormalities in schizotypal personality disorder. _Biol. Psychiatry_ 61, 1157–1160 (2007). Article  CAS  Google Scholar  * McClure, M. M. et al. Pergolide treatment of cognitive deficits

associated with schizotypal personality disorder: continued evidence of the importance of the dopamine system in the schizophrenia spectrum. _Neuropsychopharmacology_ 35, 1356–1362 (2010).

Article  CAS  Google Scholar  * McClure, M. M. et al. The effects of risperidone on the cognitive performance of individuals with schizotypal personality disorder. _J. Clin.

Psychopharmacol._ 29, 396–398 (2009). Article  Google Scholar  * Rabella, M. et al. Neurophysiological evidence of impaired self-monitoring in schizotypal personality disorder and its

reversal by dopaminergic antagonism. _Neuroimage Clin._ 11, 770–779 (2016). Article  Google Scholar  * Rosell, D. R. et al. Effects of the D1 dopamine receptor agonist dihydrexidine

(DAR-0100A) on working memory in schizotypal personality disorder. _Neuropsychopharmacology_ 40, 446–453 (2015). Article  CAS  Google Scholar  * Siegel, B. V. et al. D-amphetamine challenge

effects on Wisconsin Card Sort Test. Performance in schizotypal personality disorder. _Schizophr. Res._ 20, 29–32 (1996). Article  Google Scholar  * Serban, G. & Siegel, S. Response of

borderline and schizotypal patients to small doses of thiothixene and haloperidol. _Am. J. Psychiatry_ 141, 1455–1458 (1984). Article  CAS  Google Scholar  * Hymowitz, P., Frances, A.,

Jacobsberg, L. B., Sickles, M. & Hoyt, R. Neuroleptic treatment of schizotypal personality disorders. _Compr. Psychiatry_ 27, 267–271 (1986). Article  CAS  Google Scholar  * Bogetto, F.,

Bellino, S., Vaschetto, P. & Ziero, S. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. _Psychiatry Res._ 96, 91–98 (2000).

Article  CAS  Google Scholar  * Keshavan, M., Shad, M., Soloff, P. & Schooler, N. Efficacy and tolerability of olanzapine in the treatment of schizotypal personality disorder.

_Schizophr. Res._ 71, 97–101 (2004). Article  Google Scholar  * Markovitz, P. J., Calabrese, J. R., Schulz, S. C. & Meltzer, H. Y. Fluoxetine in the treatment of borderline and

schizotypal personality disorders. _Am. J. Psychiatry_ 148, 1064–1067 (1991). Article  CAS  Google Scholar  * Rybakowski, J. K., Drozdz, W. & Borkowska, A. Low dose risperidone in the

treatment of schizophrenia-like symptoms in high-risk subjects. _J. Clin. Psychopharmacol._ 23, 674–675 (2003). Article  CAS  Google Scholar  * Di Lorenzo, R. et al. Aripiprazole:

effectiveness and safety under naturalistic conditions. _Exp. Clin. Psychopharmacol._ 15, 569–575 (2007). Article  Google Scholar  * Gutkovich, Z., Rosenthal, R. N. & Bogdonoff, L.

Transient psychosis with psychogenic polydipsia in schizotypal patient taking fluoxetine. _Psychosomatics_ 39, 295–296 (1998). Article  CAS  Google Scholar  * Heiden, A., de Zwaan, M., Frey,

R., Presslich, O. & Kasper, S. Paroxetine in a patient with obsessive-compulsive disorder, anorexia nervosa and schizotypal personality disorder. _J. Psychiatry Neurosci._ 23, 179–180

(1998). CAS  PubMed  PubMed Central  Google Scholar  * Poyurovsky, M. Clozapine in treatment-refractory obsessive-compulsive disorder with comorbid schizotypal personality disorder. _Isr. J.

Psychiatry Relat. Sci._ 45, 219–220 (2008). PubMed  Google Scholar  * Zwier, K. J. & Rao, U. Buspirone use in an adolescent with social phobia and mixed personality disorder (cluster A

type). _J. Am. Acad. Child Adolesc. Psychiatry_ 33, 1007–1011 (1994). Article  CAS  Google Scholar  * Nordentoft, M. et al. Transition rates from schizotypal disorder to psychotic disorder

for first-contact patients included in the OPUS trial. A randomized clinical trial of integrated treatment and standard treatment. _Schizophr. Res._ 83, 29–40 (2006). Article  Google Scholar

  * Karterud, S. et al. Day hospital therapeutic community treatment for patients with personality disorders. An empirical evaluation of the containment function. _J. Nerv. Ment. Dis._ 180,

238–243 (1992). Article  CAS  Google Scholar  * McKay, D. & Neziroglu, F. Social skills training in a case of obsessive-compulsive disorder with schizotypal personality disorder. _J.

Behav. Ther. Exp. Psychiatry_ 27, 189–194 (1996). Article  CAS  Google Scholar  * Plakun, E. M., Burkhardt, P. E. & Muller, J. P. 14-year follow-up of borderline and schizotypal

personality disorders. _Compr. Psychiatry_ 26, 448–455 (1985). Article  CAS  Google Scholar  * McGlashan, T. H. Schizotypal personality disorder. Chestnut Lodge follow-up study: VI.

Long-term follow-up perspectives. _Arch. Gen. Psychiatry_ 43, 329–334 (1986). Article  CAS  Google Scholar  * Modestin, J., Foglia, A. & Toffler, G. Comparative study of schizotypal and

schizophrenic patients. _Psychopathology_ 22, 1–13 (1989). Article  CAS  Google Scholar  * Mehlum, L. et al. Personality disorders 2-5 years after treatment: a prospective follow-up study.

_Acta Psychiatr. Scand._ 84, 72–77 (1991). Article  CAS  Google Scholar  * Bender, D. S. et al. Treatment utilization by patients with personality disorders. _Am. J. Psychiatry_ 158, 295–302

(2001). Article  CAS  Google Scholar  * Grilo, C. M. et al. Two-year stability and change of schizotypal, borderline, avoidant, and obsessive-compulsive personality disorders. _J. Consult.

Clin. Psychol._ 72, 767–775 (2004). Article  Google Scholar  * Warner, M. B. et al. The longitudinal relationship of personality traits and disorders. _J. Abnorm. Psychol._ 113, 217–227

(2004). Article  Google Scholar  * McGlashan, T. H. et al. Two-year prevalence and stability of individual DSM-IV criteria for schizotypal, borderline, avoidant, and obsessive-compulsive

personality disorders: toward a hybrid model of axis II disorders. _Am. J. Psychiatry_ 162, 883–889 (2005). Article  Google Scholar  * Bernstein, D. P. et al. Prevalence and stability of the

DSM-III-R personality disorders in a community-based survey of adolescents. _Am. J. Psychiatry_ 150, 1237–1243 (1993). Article  CAS  Google Scholar  * Olin, S. S. et al. Childhood behavior

precursors of schizotypal personality disorder. _Schizophr. Bull._ 23, 93–103 (1997). Article  CAS  Google Scholar  * Asarnow, J. R. Childhood-onset schizotypal disorder: a follow-up study

and comparison with childhood-onset schizophrenia. _J. Child Adolesc. Psychopharmacol._ 15, 395–402 (2005). Article  Google Scholar  * Woods, S. W. et al. Validity of the prodromal risk

syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. _Schizophr. Bull._ 35, 894–908 (2009). Article  Google Scholar  * Farooq, S., et al.

Pharmacological interventions for schizotypal personality disorder. _Cochrane Database Syst. Rev_. CD009047 (2011). Download references ACKNOWLEDGEMENTS The authors thank Jacquie Klesing,

Board-certified Editor in the Life Sciences (ELS), for editing assistance with the manuscript. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Psychiatry and Psychotherapy,

Ludwig-Maximilians-University, Munich, Germany Sophie K. Kirchner, Astrid Roeh, Jana Nolden & Alkomiet Hasan Authors * Sophie K. Kirchner View author publications You can also search for

this author inPubMed Google Scholar * Astrid Roeh View author publications You can also search for this author inPubMed Google Scholar * Jana Nolden View author publications You can also

search for this author inPubMed Google Scholar * Alkomiet Hasan View author publications You can also search for this author inPubMed Google Scholar CONTRIBUTIONS S.K.K. and A.H. designed

the study. S.K.K. searched the literature. S.K.K. and A.R. extracted the data, and A.H. and J.N. reviewed it. All authors wrote and approved the manuscript. CORRESPONDING AUTHOR

Correspondence to Sophie K. Kirchner. ETHICS DECLARATIONS COMPETING INTERESTS In the past 5 years, A.H. received a paid speakership from Desitin, Otsuka, Janssen-Cilag, and Lundbeck. He was

previously member of an advisory boards of Roche, Otsuka, Lundbeck, and Janssen-Cilag. The authors declare no competing interests. ADDITIONAL INFORMATION PUBLISHER'S NOTE: Springer

Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. ELECTRONIC SUPPLEMENTARY MATERIAL SUPPLEMENTARY INFORMATION RIGHTS AND

PERMISSIONS OPEN ACCESS This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any

medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The

images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not

included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly

from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Kirchner, S.K.,

Roeh, A., Nolden, J. _et al._ Diagnosis and treatment of schizotypal personality disorder: evidence from a systematic review. _npj Schizophr_ 4, 20 (2018).

https://doi.org/10.1038/s41537-018-0062-8 Download citation * Received: 05 November 2017 * Revised: 15 August 2018 * Accepted: 21 August 2018 * Published: 03 October 2018 * DOI:

https://doi.org/10.1038/s41537-018-0062-8 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not

currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative